Advertisement

Community-Acquired Pneumonia Due to Nonfermenting Gram-Negative Bacilli

  • Todd F. Hatchette

Keywords

Cystic Fibrosis Chronic Granulomatous Disease Clavulanic Acid Nosocomial Pneumonia Burkholderia Cepacia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Achar, K. N., Mohini, M. J., Achar, M. N., & Menon, N. K. (1993a). Community acquired bacteraemic Acinetobacter pneumonia with survival. Postgrad. Med. J., 69, 934–937.PubMedGoogle Scholar
  2. Achar, K. N., Johny, M., Achar, M. N., & Monon, N. K. (1993b). Community-acquired Acinetobacter pneumonia with survival. Postgrad. Med. J., 69, 934–937.PubMedGoogle Scholar
  3. Anstey, N. M., Currie, B. J., & Withnall, K. M. (1992). Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia. Clin. Infect. Dis., 14, 83–91.PubMedGoogle Scholar
  4. Baltimore, R. S., Duncan, R. L., Shapiro, E. D., & Edberg, S. C. (1989). Epidemiology of pharyngeal colonization of infants with aerobic gram-negative rod bacteria. J. Clin. Micro-biol., 27, 91–95.Google Scholar
  5. Barnes, D. J., Naraqi, S., & Igo, J. D. (1988). Community-acquired Acinetobacter pneumonia in adults in Papua New Guinea. Rev. Infect. Dis., 10, 636–639.PubMedGoogle Scholar
  6. Bergogne-Berezin, E., & Towner, K. J. (1996). Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical and epidemiological features. Clin. Microbiol. Rev., 9, 148–165.PubMedGoogle Scholar
  7. Bergogne-Berezin, E. (1999). Acinetobacter species, in: Antimicrobial Therapy and Vaccines (V. Yu, T. C. Merigan, S. L. Barriere, A. M. Suga, D. Raoult, C. Peloquin, & M. Iseman, eds.). Baltimore: Williams and Wilkins, pp. 3–9.Google Scholar
  8. Bernasconi, E., Wust, T., Speich, R., Flury, G., & Krause, M. (1993). Community-acquired Acinetobacter pneumonia. Schweiz. Med. Wochenschr., 123, 1566–1571.PubMedGoogle Scholar
  9. Bick, J. A., & Semel, J. D. (1993). Fulminant community-acquired Acinetobacter pneumonia in a healthy woman. Clin. Infect. Dis., 17, 820–821.PubMedGoogle Scholar
  10. Bilgic, H., Akin, E. S., Tasan, Y., Ekiz, K., & Serber, O. (1995). A case of Acinetobacter calcoaceticus pneumonia. Thorax, 50, 315–316.PubMedGoogle Scholar
  11. Bottone, E. J., Douglas, S. D., Rausen, A. R., & Keusch, G. T. (1975). Association of Pseudomonas cepacia with chronic granulomatous disease. J. Clin. Microbiol., I, 425–428.Google Scholar
  12. Burdge, D. R., Noble, M. A., Campbell, M. E., Krell, V. L., & Speert, D. P. (1995). Xanthomonas maltophilia misiden-tified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin. Infect. Dis., 20, 445–448.PubMedGoogle Scholar
  13. Burdon, D. W., & Whitby, J. L. (1967). Contamination of hospital disinfectants with Pseudomonas species. Br. Med. J., 2, 153–155.PubMedGoogle Scholar
  14. Butler, S. L., Doherty, C. J., Hughes, J. E., Nelson, J. W., & Govan, J. R. W. (1995). Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? J. Clin. Microbiol., 33, 1001–1004.PubMedGoogle Scholar
  15. Chow, A. W., Wong, J., & Bartlett, K. H. (1988). Synergistic interactions of ciprofloxacin and extended spectrum β-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia. Antimicrob. Agents Chemother., 32, 782–784.PubMedGoogle Scholar
  16. Christenson, J. C., Welch, D. F., Mukwaya, G., Muszynski, M. J., Weaver, R. E., & Brenner, D. J. (1989). Recovery of Pseudomonas gladioli from respiratory tract specimens of patients with cystic fibrosis. J. Clin. Microbiol., 27, 270–273.PubMedGoogle Scholar
  17. Cohen, M. S., Knowles, M. R., & Yankaskas, J. R. (1993). Infection due to Pseudomonas cepacia. Clin. Infect. Dis., 17, 291–292.PubMedGoogle Scholar
  18. Cordes, L. G., Brink, E. W., Checko, P. J., Lentnek, A., Lyons, R. W., Hayes, P. S., Wu, T. C., Tharr, D. G., & Fraser, D. W. (1981). A cluster of Acinetobacter pneumonia in foundry workers. Ann. Intern. Med., 95, 688–693.PubMedGoogle Scholar
  19. Currie, B., Fisher, D., Anstey, N., & Withnall, K. (1994). Community-acquired Acinetobacter pneumonia. Postgrad. Med. J., 69, 766.Google Scholar
  20. Dees, S. B., Hollis, D. G., Weaver, R. E., & Moss, W. (1983). Cellular fatty acid composition of Pseudomonas marginata and closely associated bacteria. J. Clin. Microbiol., 18, 1073–1078.PubMedGoogle Scholar
  21. Denney, D., Bigley, R. H., Rashad, A. L., MacDonald, W. J., & Miller, M. J. (1975). Recurrent pneumonitis due to Pseudommonas cepacia—-an unexpected phagocyte dysfunction. West. J. Med., 122, 160–164.PubMedGoogle Scholar
  22. Denton, M., & Kerr, K. G. (1998). Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin. Microbiol. Rev., 11, 57–80.PubMedGoogle Scholar
  23. Domingo, P., Munoz, R., Frontera, G., Pericas, R., & Martinez, E. (1995). Community-acquired pneumonia due to Acinetohacter lwoffii in a patient with the human immunodeficiency virus. Clin. Infect. Dis., 21, 205–206.Google Scholar
  24. Ederer, G. M., & Matsen, J. M. (1972). Colonization and infection with Pseudomonas cepacia. J. Infect. Dis., 125, 613–618.PubMedGoogle Scholar
  25. Franzetti, F., Cernuschi, M., Esposito, R., & Moroni, M. (1992). Pseudomonas infections in patients with AIDS and AIDS-related complex. J. Intern. Med., 231, 437–441.PubMedCrossRefGoogle Scholar
  26. Gilardi, G. L. (1970). Characterization of EO-1 strains (Pseudomonas kingii) isolated from clinical specimens and the hospital environment. Appl. Microbiol., 20, 521–522.PubMedGoogle Scholar
  27. Goodhart, G. L., Abrutyn, E., Watson, R., Root, R. K., & Egert, J. (1977). Community-acquired Acinetobacter calcoaceticus var antiratus pneumonia. JAMA, 238, 516–518.CrossRefGoogle Scholar
  28. Govan, J. R. W., Brown, P. H., Maddison, J., Doherty, C. J., Nelson, J. W., Dodd, M., Greening, A. P., & Webb, A. K. (1993). Evidence of transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet, 342. 15–19.PubMedCrossRefGoogle Scholar
  29. Hamer, L., & Parker, H. W. (1996). Treatment of cystic fibrosis in adults. Am. Fam. Phys., 54, 1291–1297.Google Scholar
  30. Heath, T., & Currie, B. (1995). Nosocomial and community-acquired Xanthomonas maltophilia infection in tropical Australia. J. Hosp. Infect., 30, 309–313.PubMedCrossRefGoogle Scholar
  31. Henderson, S. T, Torrez, A. J., & Clement, K. D. (1987). Community-acquired nonbacteremic Acinetobacter pneumonia. J. Fam. Pract., 25, 609–610.PubMedGoogle Scholar
  32. Irifune, K., Ishida, T., Shimoguchi, K., Ohtake, J., Tanaka, T., Morikawa, N., Kaku, M., Koga, H., Kohno, S., & Hara, K. (1994). Pneumonia caused by Stenotrophomonas maltophilia with a mucoid phenotype. J. Clin. Microbiol., 31, 2856–2857.Google Scholar
  33. Kanj, S. S., Tapson, V., Davis, R. D., Madden, J., & Browning, I. (1997). Infections in patients with cystic fibrosis following lung transplantation. Chest, 112, 924–930.PubMedGoogle Scholar
  34. Karalus, N. C., Cursons, R. T, Leng, R. A., Mahood, C. B., Rothwell, R. P. G., Hancock, B., Cepulis, S., Wawatai, M., & Coleman, L. (1991). Community acquired pneumonia: aetiology and prognostic index evaluation. Thorax, 46, 413–418.PubMedCrossRefGoogle Scholar
  35. King, E. O. (1967). The identification of unusual pathogenic gram negative bacteria (revised). National Communicable Disease Center, Atlanta, Georgia.Google Scholar
  36. Koneman, E. W., Allen., S. D., Janda, W. M., Schreckenberger, P. C, & Winn, W. C. (eds.). (1997). The non-fermentative gramnegative bacilli, in: Color Atlas and Textbook of Diagnostic Microbiology, 5th ed. Philadelphia: Lippincott, pp. 253–320.Google Scholar
  37. Ledson, M. J., Gallagher, M. J., & Walshaw, M. J. (1998a). Chronic Burkholderia cepacia bronchiectasis in a non-cystic fibrosis individual. Thorax, 53, 430–432.PubMedGoogle Scholar
  38. Ledson, M. J., Gallagher, M. J., Corkill, J. E., Hart, C. A., & Walshaw, M. J. (1998b). Cross infection between cystic fibrosis patients colonized with Burkholderia cepacia. Tho-rax, 53, 432–436.Google Scholar
  39. Levison, M. E., & Kaye, D. (1985). Pneumonia caused by gram-negative bacilli: an overview. Rev. Infect. Dis., 7, S656–S665.PubMedGoogle Scholar
  40. LiPuma, J. J., Dasen, S. E., Nielson, D. W., Stern, R. C., & Stull, T. L. (1990). Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet, 336, 1094–1096.PubMedCrossRefGoogle Scholar
  41. Mengistu, Y., & Gedebou, M. (1986). Aerobic gramnegative pharyngeal bacilli of adult Ethiopians: carrier rates and antibiograms. J. Hyg., 97, 247–253.CrossRefGoogle Scholar
  42. Muder, R. R. (1999). Stenotrophomonas (Xanthomonas) maltophilia, in: Antimicrobial Therapy and Vaccines (V. Yu, T.C. Merigan, S. L. Barriere, A. M. Suga, D. Raoult, C. Peloquin, & M. Iseman, eds.). Baltimore: Williams and Wilkins, pp. 417–419.Google Scholar
  43. Muder, R. R., Harris, A. P., Muller, S., Edmond, M., Chow, J. W., Papadakis, K., Wagener, M. W., Bodey, G. P., & Steckelberg, J. M. (1996). Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective multicenter study of 91 episodes. Clin. Infect. Dis., 22, 508–512.PubMedGoogle Scholar
  44. Nagai, T. (1984). Association of Pseudomonas maltophilia with malignant lesions. J. Clin. Microbiol., 20, 1003–1005.PubMedGoogle Scholar
  45. O’Neil, K. M., Herman, J. H., Modlin, J. F., Moxon, E. R., & Winkelstein, J. A. (1986). Pseudomonas cepacia: an emerging pathogen in chronic granulomatous disease. J. Pediatr., 108, 940–942.Google Scholar
  46. Patel, M. S., Phillips, C. B., & Cabaron, Y. (1991). Frequent hospital admissions for bacterial infections among Aboriginal people with diabetes in central Australia. Med. J. Aust., 155, 218–222.PubMedGoogle Scholar
  47. Pegues, D. A. (1999). Burkholderia cepacia, in: Antimicrobial Therapy and Vaccines (V. Yu, T. C. Merigan, S. L. Barriere, A. M. Suga, D. Raoult, C. Peloquin, & M. Iseman, eds.). Baltimore: Williams & Wilkins, pp. 89–93.Google Scholar
  48. Poe, R. H., Marcus, H. R., & Emerson, G. L. (1977). Lung abscess due to Pseudomonas cepacia. Am. Rev. Respir. Dis., 115, 861–865.PubMedGoogle Scholar
  49. Poulos, C. D., Matsumura, S. O., Willey, B. M., Low, D. E., & McGeer, A. (1995). In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob. Agents Chemother., 39, 2220–2223.PubMedGoogle Scholar
  50. Pujol, M., Corbella, X., Carratala, J., & Gudiol, F. (1992). Community-acquired bacteremic Pseudomonas cepacia pneumonia in an immunocompetent host. din. Infect. Dis., 15, 887–888.Google Scholar
  51. Ramsey, B. W. (1996). Management of pulmonary disease in patients with cystic fibrosis. N. Engl. J. Med., 335, 179–188.PubMedCrossRefGoogle Scholar
  52. Rosenthal, S., & Tager, I. B. (1975). Prevalence of gramnegative rods in the normal pharyngeal flora. Ann. Intern. Med., 83, 355–357.PubMedGoogle Scholar
  53. Ross, J. P., Holland, S. M., Gill, V. J., DeCarlo, E. S., & Gallin, J. I. (1995). Severe Burkholderia (Pseudomonas) gladioli infection in chronic granulomatous disease: report of two successfully treated cases. Clin. Infect. Dis., 21, 1291–1293.PubMedGoogle Scholar
  54. Rudin, M. L., Michael, J. R., & Huxley, E. J. (1979). Community-acquired Acinetobacter pneumonia. Am. J. Med., 67, 39–43.PubMedCrossRefGoogle Scholar
  55. Saiman, L., Cacalano, G., & Prince, A. (1990). Pseudomonas cepacia adherence to respiratory epithelial cells is enhanced by Pseudomonas aeruginosa. Infect. Immun., 58, 2578–2584.PubMedGoogle Scholar
  56. Sakar, T. K., Gilardi, G., Aguam, A. S., Josephson, J., & Leventhal, G. (1979). Primary Pseudomonas maltophilia infection of the lung. Postgrad. Med., 165, 253–256.Google Scholar
  57. Smith, D. L., Gumery, L. B., Smith, E. G., Stableforth, D. E., Kaufmann, M. E., & Pitt, T. L. (1993). Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission. J. Clin Microbiol., 31, 3017–3022.PubMedGoogle Scholar
  58. Sonnenwirth, A. C. (1970). Bacteremia with and without meningitis due to Yersinia Enterocolitica, Edwardsiella tarda, Comamonas Terrigena, and Pseudomonas maltophilia. Ann. NY Acad. Sci., 174, 488–502.PubMedGoogle Scholar
  59. Spangler, S. K., Visalli, M. A., Jacobs, M. R., & Appelbaum, P. C. (1996). Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, d-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem. Antimicrob. Agents Chemother., 40, 772–775.PubMedGoogle Scholar
  60. Tablan, O. C., Martone, W. J., Doershuk, C. F., Stern, R. C., Thomassen, M. J., Klinger, J. D., White, J. W., Carson, L. A., & Jarvis, W. R. (1987). Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis: risk factors and outcomes. Chest, 91, 527–532.PubMedGoogle Scholar
  61. Thomassen, M. J., Demko, C. A., Klinger, J. D., & Stern, R. C. (1985). Pseudomonas cepacia colonization among patients with cystic fibrosis: a new opportunist. Am. Rev. Respir. Dis., 131, 791–796.PubMedGoogle Scholar
  62. VanCouwenberghe, C. J., Farver, T. B., & Cohen, S. H. (1997). Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect. Control Hosp. Epidemiol., 18, 316–321.PubMedCrossRefGoogle Scholar
  63. Vartivarian, S., Anaissie, E., Bodey, G., Sprigg, H., & Rolston, K. (1994). A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob. Agents Chemother., 38, 624–627.PubMedGoogle Scholar
  64. Visalli, M. A., Bajaksouzian, S., Jacobs, M. R., & Appelbaum, P. C. (1997). Comparative activity of trovafloxacin, alone and in combination with other agents, against gramnegative nonfermentative rods. Antimicrob. Agents Chemother., 41, 1475–1481.PubMedGoogle Scholar
  65. Visalli, M. A., Jacobs, M. R., & Appelbaum, P. C. (1998). Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia. Antimicrob. Agents Chemother., 42, 2002–2005.PubMedGoogle Scholar
  66. Von Graevenitz, A. (1995). Acinetobacter, Alcaligenes, Moraxella, and other nonfermentive gram-negative bacteria, in: Manual of Clinical Microbiology, 6th ed. (P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, & Yolken, R. H., eds.). Washington: ASM Press, pp. 520–532.Google Scholar
  67. Wallace, R. J., Awe, R. J., & Martin, R. R. (1976). Bacteremic Acinetobacter (Herellea) pneumonia with survival-case report. Am. Rev. Respir. Dis., 113, 695–699.PubMedGoogle Scholar
  68. Yamagishi, Y., Fujita, J., Takigawa, K., Negayama, K., Nakazawa, T., & Takahara, J. (1993). Clinical features of Pseu-domanas cepacia pneumonia in a epidemic among immunocompromised patients. Chest, 103, 1706–1709.PubMedGoogle Scholar
  69. Yang, C. H., Chen, K. J., & Wang, C. K. (1997). Community acquired Acinetobacter pneumonia: a case report. J. Infect., 35, 316–318.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Todd F. Hatchette
    • 1
  1. 1.Department of MedicineDalhousie UniversityHalifaxCanada

Personalised recommendations